source
- Infinimmune secures $75 million Series A to develop longer-lasting eczema antibody therapiesInfinimmune, a biotech based in Alameda, California, announced on Tuesday that it has closed a $75 million Series A financing round. The capital will support the development of its first two clinic…
- Hims & Hers says it can quickly launch six wellness peptides if FDA lifts banHims & Hers used its second‑quarter earnings call to explain that it is preparing to offer six consumer wellness peptides that are currently prohibited for compounding pharmacies. The company says…